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ABSTRACT
Background. Nephrotic-range proteinuria (NRP) is associated with rapid kidney function loss and increased cardiovascular
(CV) disease risk. We assessed the effects of linagliptin (LINA) on CV and kidney outcomes in people with Type 2 diabetes
(T2D) with or without NRP.
Methods. Cardiovascular and renal microvascular outcome study with LINA randomized participants with T2D and CV
disease and/or kidney disease to LINA 5 mg or placebo (PBO). The primary endpoint [time to first occurrence of 3-point
major adverse cardiac events (3P-MACE)], and kidney outcomes, were evaluated by NRP status [urinary albumin:creatinine
ratio (UACR)2200 mg/g] at baseline (BL) in participants treated with one or more dose of study medication.
Results. NRP was present in 646/6979 [9.3% (LINA/PBO n¼317/n¼329); median UACR 3486 (Q1: 2746/Q3: 4941) mg/g]
participants, who compared with no-NRP were younger (62.3/66.1 years) and had lower estimated glomerular filtration rate
(eGFR) (39.9/56.1 mL/min/1.73 m2). Over a median of 2.2 years, 3P-MACE occurred with a 2.0-fold higher rate in NRP versus
no-NRP (PBO group), with a neutral LINA effect, regardless of NRP. The composite of time to renal death, end-stage kidney
disease (ESKD) or decrease of 40 or 50% in eGFR, occurred with 12.3- and 13.6-fold higher rate with NRP (PBO group);
evidence of heterogeneity of effects with LINA was observed for the former [NRP yes/no: hazard ratio 0.80 (0.63–1.01)/1.25
(1.02–1.54); P-interaction 0.005], but not the latter [0.83 (0.64–1.09)/1.17 (0.91–1.51), P-interaction 0.07]. No heterogeneity was
observed for renal death or ESKD [0.88 (0.64–1.21)/0.94 (0.67–1.31), P-interaction 0.79]. Glycated haemoglobin A1c (HbA1c)
was significantly reduced regardless of NRP, without increasing hypoglycaemia risk. Regression to normoalbuminuria [1.20
(1.07–1.34)] and reduction of UACR50% [1.15 (1.07–1.25)] from BL, occurred more frequently with LINA, regardless of NRP
status (P-interactions >0.05).
Conclusions. Individuals with T2D and NRP have a high disease burden. LINA reduces their albuminuria burden and HbA1c,
without affecting CV or kidney risk.
Keywords: albuminuria, DPP-4 inhibitor, HbA1c, kidney disease, linagliptin, renal impairment, Type 2 diabetes
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INTRODUCTION
The study of glucose-lowering medications for Type 2 diabetes
(T2D) has evolved from prioritizing glycaemic control to also
assessing the relative cardiovascular (CV) risks and benefits in
people with T2D and established CV disease [1]. As a result, there
have been important updates to treatment guidelines and recom-
mendations globally [2–4]. Yet, despite a clear advancement in CV
risk management, few studies have assessed the use of glucose-
lowering medications in those with T2D who suffer chronic kid-
ney disease (CKD), although over the last few years some dedi-
cated studies have been reported [5]. Up to 40% of people with T2D
will develop CKD [6], which is associated with reduced quality of
life [7, 8] and lower glycaemic goal attainment [9, 10]. A substantial
number of people develop nephrotic-range proteinuria (NRP) or
the nephrotic syndrome [11], and these people are at particularly
high risk of progression to end-stage kidney disease (ESKD) [12].
T2D is a common cause of NRP in adults. People with T2D and
NRP represent an understudied group [12, 13] with a particular
clinical challenge, given the graded increase in risk for most com-
plications with higher albuminuria categories [14]. The risk is fur-
ther accentuated for accelerated loss of kidney function and
increased risk for hospitalizations, and many die with NRP before
reaching ESKD requiring kidney replacement therapy [15–18].
The choice of glucose-lowering therapies is limited in lower
ranges of kidney function due to drug accumulation and side
effects, as are the data on the safety and efficacy of glucose-
lowering therapies in people with T2D and NRP, since the ma-
jority of recent CV outcome trials in T2D do not include people
with NRP [5]. Management of these concomitant comorbidities
focuses on controlling traditional risk factors for further pro-
gression of kidney disease [e.g. blood pressure (BP), weight and
glucose] [19], and use of angiotensin-converting enzyme (ACE)
inhibitors/angiotensin-receptor blockers (ARBs) [20] for addi-
tional nephroprotection and/or control of albuminuria. There
have been no new nephroprotective treatments to manage pro-
teinuria in NRP since the introduction of ARBs in the early
2000s, although mineralocorticoid-receptor antagonists appear
to be promising in NRP, with the caveat of potassium increase
[21], as well as sodium–glucose co-transporter-2 (SGLT-2) inhibi-
tors, owing to their kidney-targeted mechanism of action and
demonstrated benefits in individuals with T2D [22–25].
Linagliptin (LINA), a dipeptidyl-peptidase 4 inhibitor (DPP-4i)
approved for glycaemic management of T2D, does not require
dose adjustment in people with CKD as it is 85% eliminated via
biliary excretion [26]. Its CV and kidney safety were confirmed
in the CArdiovascular and Renal Microvascular outcomE study
with LINA (CARMELINA) trial [20, 27], in which 6979 individuals
with CKD [3000 with estimated glomerular filtration rate (eGFR)
<45 mL/min/1.73 m2; 2690 with urinary albumin creatinine ratio
(UACR) >300 mg/g] were studied. In this trial, LINA also reduced
albuminuria progression and glycated haemoglobin A1c
(HbA1c), regardless of eGFR at baseline (BL), including in those
with eGFR<30 mL/min/1.73 m2 [28]. As there was no upper limit
for UACR for inclusion in CARMELINA, it is also well positioned
to study people with NRP and T2D, and to evaluate the safety
and efficacy of LINA in this understudied group.
MATERIALS AND METHODS
Study design and procedures
The study design and primary results have been reported previ-
ously [27, 29]. In brief, CARMELINA (NCT01897532) was a
multicentre, randomized, double-blind clinical outcome trial in
adults with T2D [HbA1c 6.5–10.0% (48–86 mmol/mol)] at high risk
for CV and kidney disease defined as history of CV disease and
UACR>30 mg/g (or equivalent) or eGFR 45–75 mL/min/1.73 m2 and
UACR>200 mg/g (or equivalent) or eGFR 15–45 mL/min/1.73 m2 re-
gardless of UACR. It was conducted at 605 centres in 27 countries.
Investigators were encouraged to use additional CV medications
(e.g. statins and antihypertensive therapies) and medications for
glycaemic control [except DPP-4i, glucagon-like peptide (GLP)-1 re-
ceptor agonists and SGLT-2 inhibitors] according to applicable
standards of care throughout the trial. Participants who prema-
turely discontinued study medication were followed for ascer-
tainment of CV and key secondary kidney outcome events, as
previously described [28]. Attempts were made to collect vital sta-
tus information on every randomized patient at study comple-
tion, in compliance with local law and regulations. The protocol
was approved by Institutional Review Boards or Ethics
Committees for each participating site and all participants pro-
vided written informed consent for trial participation.
Classification of NRP
UACR was measured by a central laboratory on a first-morning
void specimen, at screening; randomization (BL); at Weeks 36
and 84; then every year until the end of study visit; at the end of
study visit; and 30 days after the end of study visit. Albuminuria
categorization at BL was predefined based on KDIGO definitions
as <30, 30–300 and >300 mg/g [16]. Additionally, NRP was de-
fined as UACR>2200 mg/g creatinine with any GFR [29], a defini-
tion also used elsewhere [11].
Outcomes
CV and kidney outcomes. We compared the treatment effects of
LINA versus placebo (PBO) in participants with NRP versus with-
out NRP (no NRP) with a time to first event analysis of the pri-
mary outcome of the trial [CV death, non-fatal myocardial
infarction or non-fatal stroke (3-point major adverse cardiac
event, 3P-MACE)], CV death, all-cause mortality, hospitalization
for heart failure and all-cause hospitalization and the following
kidney outcomes: (i) the composite of renal death, sustained
ESKD or sustained decrease of40% eGFR from BL (key secondary
kidney outcome); (ii) the composite of renal death, sustained
ESKD or sustained decrease of 50% or more in eGFR from BL; (iii)
the composite of renal death or ESKD; (iv) the composite of renal
death, ESKD or sustained eGFR<10 mL/min/1.73 m2; and (v) the
composite of renal death, ESKD or doubling of serum creatinine.
Effects on eGFR were assessed by an eGFR [Modification of Diet in
Renal Disease (MDRD)] slope analysis (change per year) from BL
to last value on-treatment (LVOT) by NRP at BL, and from BL to
Week 12 (change/4 weeks) and Week 12 to LVOT (change/year).
All data available for eGFR were used to calculate the slope.
Albuminuria endpoints. Albuminuria endpoints were pre-
defined and post hoc defined (Supplementary data, Table S1) and
analysed as time to new onset of albuminuria regression, and
improvement in albuminuria status relative to BL (reduction
50% or 30% from BL UACR, respectively). In addition, in those
with NRP at BL, regression to no NRP was analysed. Analysis
was also conducted by applying a sustained criterion, i.e. re-
quirement of having results confirmed in two or more consecu-
tive measurements that were 28 days apart.
Efficacy and safety endpoints. Additional endpoints by NRP at
BL were change from BL in HbA1c, and occurrence of adverse






/ckj/article/14/1/226/6102818 by guest on 15 February 2021
events (AEs) in general and specifically hypoglycaemia. The lat-
ter two were captured based on investigator reported events
and coded using the Medical Dictionary for Drug Regulatory
Activities version 20.1.
Statistical analyses
P-values for association of BL characteristics between NRP groups
were obtained from Chi-square test for categorical variables and
from t-test for continuous variables (after log transformation for
UACR). Time-to-event outcomes were analysed using Cox propor-
tional hazards regression models, with randomized treatment
and geographical region as factors. For NRP subgroup analyses,
an additional factor for NRP subgroup as well as NRP subgroup-
by-treatment interaction term was included in the regression
models. Censoring was applied the day a participant was last
known to be free of the specific outcome event. All analyses were
performed using the intention-to-treat principle, modified to ex-
clude randomized participants who did not take any dose of
study medication (treated set). Handling of missing data is de-
scribed in the statistical analysis plan published elsewhere [27].
A formal test of heterogeneity of the treatment effect among
subgroups was performed for each subgroup analysis. A two-
sided P< 0.05 was considered significant for all analyses with
no adjustments made for multiple testing. The iteratively mea-
sured continuous parameter HbA1c was analysed using mixed-
effect models for repeated measures including randomized
treatment, region, week, treatment by week interaction, linear
covariates of BL measurement and BL by week interaction in
the model. Overall safety assessments were conducted using
descriptive statistics for AEs. Analyses were conducted with
SAS version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Of 6979 randomized and treated participants followed for me-
dian of 2.2 years, 646 (9.3%) had NRP at BL (Table 1). People with
Table 1. BL characteristics [n (%), mean (standard deviation) unless otherwise stated] of participants with and without NRP
NRP No NRP Overall P-value NRP versus no NRP
n (%) 646 (100) 6330 (100) 6979 (100)
Age, years 62.3 (9.3) 66.1 (9.0) 65.9 (9.10) <0.001
Men, n (%) 387 (59.9) 4001 (63.2) 4390 (62.9) 0.098
Women, n (%) 259 (40.1) 2329 (36.8) 2588 (37.1)
Region, n (%)
Europe (including South Africa) 207 (32.0) 2724 (43.0) 2934 (42.0) <0.001
Latin America 273 (42.3) 2037 (32.2) 2310 (33.1)
North America 95 (14.7) 1085 (17.1) 1180 (16.9)
Asia 71 (11.0) 484 (7.6) 555 (8.0)
Smoking status
Never smoked 349 (54.0) 3402 (53.7) 3751 (53.8) 0.53
Ex-smoker 223 (34.5) 2284 (36.1) 2507 (35.9)
Currently smokes 73 (11.3) 638 (10.1) 711 (10.2)
Missing 1 (0.2) 6 (0.1) 7 (0.1)
eGFR (MDRD), mL/min/1.73 m2 39.9 (21.6) 56.1 (24.8) 54.6 (25.0) <0.001
90 25 (3.9) 703 (11.1) 728 (10.4) <0.001
60 to <90 82 (12.7) 1820 (28.8) 1902 (27.3)
45 to <60 92 (14.2) 1256 (19.8) 1348 (19.3)
30 to <45 197 (30.5) 1740 (27.5) 1937 (27.8)
15 to <30 242 (37.5) 798 (12.6) 1040 (14.9)
<15 8 (1.2) 13 (0.2) 21 (0.3)
UACR, median (25th to 75th percentile), mg/g 3486 (2746, 4941) 129 (38, 461) 162 (44–728) <0.001
UACR, n (%)
<30 mg/g 0 1392 (22.0) 1392 (19.9) <0.001
30–300 mg/g 0 2894 (45.7) 2894 (41.5)
>300 mg/g 646 (100) 2044 (32.3) 2690 (38.5)
HbA1c, % 8.1 (1.0) 7.9 (1.0) 7.95 (1.0) <0.001
Diabetes duration, years 16.2 (8.9) 14.6 (9.5) 14.8 (9.5) <0.001
Body mass index, kg/m2 30.9 (5.5) 31.3 (5.3) 31.2 (5.3) 0.06







Insulin 459 (71.1) 3490 (55.1) 3950 (56.6) <0.001
Metformin 236 (36.5) 3569 (56.4) 3808 (54.6) <0.001
SU 151 (23.4) 2090 (33.0) 2242 (32.1) <0.001
Any antihypertensives, n (%) 627 (97.1) 6061 (95.8) 6691 (95.9) 0.11
ACE inhibitors or ARBs 530 (82.0) 5125 (81.0) 5658 (81.1) 0.50
Statins, n (%) 450 (69.7) 4566 (72.1) 5018 (71.9) 0.18
Total cholesterol, mg/dL 204.2 (61.9) 168.5 (45.4) 171.8 (48.3) <0.001
LDL-cholesterol, mg/dL 112.8 (50.8) 88.9 (37.6) 91.1 (39.6) <0.001
HDL-cholesterol, mg/dL 47.4 (15.2) 44.2 (12.7) 44.5 (12.9) <0.001
Missing albuminuria data from three participants, therefore overall not always identical to the sum of subgroups (NRP þ no NRP). P-values obtained from Chi-square
test for categorical variables and from t-test for continuous variables (after log transformation for UACR). LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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NRP versus those without (Table 1) tended to be younger, had
lower mean eGFR, higher UACR, higher HbA1c and longer dura-
tion of T2D, had more often insulin therapy, and had a higher
systolic BP and low-density lipoprotein cholesterol. Despite no
stratification by NRP, randomization to either LINA or PBO was
balanced (Supplementary data, Table S2).
CV and kidney outcomes
Incidence rates for all outcomes were consistently higher in
patients with NRP at BL. Specifically, those with NRP in the PBO
group (Figure 1) showed a >2-fold higher rate for CV events, and
10- to 14-fold higher rates for kidney events. The incidence rates
did not appear to be influenced by sex (Supplementary data,
Figure S1A and B).
Overall, regardless of NRP status, there was no difference be-
tween LINA versus PBO with respect to 3P-MACE [hazard ratio
(HR) 1.02 (95% confidence interval, CI 0.89–1.17)], CV mortality
[0.96 (0.81–1.14)], all-cause mortality [0.98 (0.84–1.13)], all-cause
hospitalization [0.93 (0.85–1.00)] or hospitalization for heart fail-
ure [0.90 (0.74–1.08)]; the corresponding results do not indicate
that NRP is an effect modifier (all interaction P> 0.05) (Figure 2).
Overall, there was also no difference between the key secondary
endpoint [renal death, sustained ESKD or sustained decrease of
40% in eGFR from BL; 1.04 (0.89–1.22)], renal death, sustained
ESKD or sustained decrease of 50% in eGFR from BL [0.98 (0.82–
1.18)], renal death or sustained ESKD [0.87 (0.69–1.10)], the com-
posite renal endpoint of renal death, ESKD or eGFR <10 mL/
min/1.73 m2 [0.84 (0.67–1.05)] or the composite renal endpoint of
renal death, ESKD or doubling of creatinine [0.92 (0.77–1.11)], for
LINA versus PBO. When assessed by NRP status (Figure 2), some
heterogeneity was observed for LINA versus PBO for the key sec-
ondary outcome of renal death, sustained ESKD or sustained de-
crease of 40% in eGFR [NRP yes/no: 0.80 (0.63–1.01)/1.25 (1.02–
1.54); P for interaction 0.005], but not for the other kidney out-
comes, including the analysis using a 50% eGFR reduction or
doubling of creatinine, in a corresponding composite endpoint
[NRP yes/no: 0.83 (0.64–1.09)/1.17 (0.91–1.51), P for interaction
0.07 and NRP yes/no: 0.81 (0.62–1.06)/1.09 (0.84–1.41), P for inter-
action 0.13]. Also no heterogeneity of the effect was observed
for the composite renal death or ESKD [NRP yes/no: 0.88 (0.64–
1.21)/0.94 (0.67–1.31), P for interaction 0.79].
A 3-fold greater decline in eGFR per year was seen in those
with NRP (NRP eGFR slopes: LINA 6.51 mL/min/1.73 m2 versus
PBO 7.07 mL/min/1.73 m2) relative to those without NRP (no
NRP slopes: LINA 2.10 mL/min/1.73 m2 versus PBO 1.84 mL/
min/1.73 m2), but the loss in eGFR over time was not different
between the treatment groups (Figure 3A). However, consider-
ing only the first 12 weeks (Figure 3B), a significant modest rela-
tive slope reduction was observed with LINA versus PBO in
those without NRP at BL (0.25 6 0.08/4 weeks; P¼ 0.002), that
was attenuated for the period Week 12 to LVOT (0.04 6 0.17/
year; P¼ 0.81). No significant effects on eGFR slopes was
observed for those with NRP in either of these time windows.
Effect on albuminuria
Overall, in participants randomized to LINA, a significantly
higher proportion regressed to normoalbuminuria [1.20
(1.07–1.34)], as well manifesting an UACR reduction of 30%
from BL [1.14 (1.06–1.22)] or UACR reduction of 50% from
BL [1.15 (1.07–1.25)], with consistent treatment effects inde-
pendent of NRP (all interaction P> 0.05). Attenuated effects
for all albuminuria regression endpoints were seen when
analysis applied the sustained reduction of UACR criterion,
both overall and by NRP, e.g. HR for UACR reduction of
50% from BL was 1.10 (1.00–1.21) with interaction P ¼ 0.43
(Figure 4).
Considering participants with NRP at BL, a numerically
higher proportion regressed to no NRP range [1.22 (0.98–1.52)],
also in the sustained analysis [1.18 (0.92–1.51)], but neither met
the statistical significance criterion (P-values 0.08 and 0.19,
respectively).
Effect on HbA1c, hypoglycaemia and AEs. Difference in HbA1c
over the full study duration based on least square means fav-
oured LINA [0.36 (0.42 to 0.29)%], not indicating a different
effect by NRP [0.41 (0.63 to 0.19)] and no NRP [0.35 (0.42
to 0.29)], without an increase in hypoglycaemia (Table 2). The
proportion of participants with hypoglycaemia was, however,
higher in the NRP versus no NRP in both treatment groups.
Severe hypoglycaemic AEs were observed in low numbers in
those with NRP (Supplementary data, Figure S1), with numeri-
cally more events in the LINA [20 (6.3%)] than the PBO group [10
(3.0%)]; IRR 2.03 (0.95–4.35).
AEs. Generally, AEs occurred more frequently in patients with
NRP compared with no NRP participants. However, the fre-
quency of any AEs, serious AEs and AEs leading to study drug
discontinuation was similar between the treatment groups, in-
dependent of NRP at BL (Table 2).
DISCUSSION
This analysis of 646 individuals with NRP and T2D represents
one of the largest cohorts of individuals with these conditions
studied to date. The results underscore the clinical challenge
faced by T2D complicated with NRP; younger age, longer T2D
duration and poorer glycaemic control, where when metformin
use is restricted leading to increased insulin use. Furthermore,
those with NRP had more poorly controlled systolic BP, a 2-fold































































































FIGURE 1: PBO group incidence rates for CV events, heart failure and all-cause
hospitalization and renal outcomes in participants with NRP at BL or without
NRP (no NRP) at BL. ’’ denotes the relative higher event rate in NRP relative to
no NRP.
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kidney complications, including a 3-fold faster decline in eGFR.
The trial also demonstrated that LINA treatment was associated
with improvements in albuminuria and glycaemic control,
without increasing hypoglycaemia risk, but did not affect CV or
kidney risk among people with NRP, for whom few data have
previously been published.
As remission of proteinuria may lead to symptomatic im-
provement, as well as being a marker of risk reduction in people
with NRP [30], the observation of a significant, yet modest, in-
creased proportion with regression to normoalbuminuria, as
well as reduction of UACR50% from BL, including in individu-
als with NRP, is interesting, and important. A previous smaller
trial indicated that regression of NRP, defined as a reduction in
albuminuria from NRP (defined as persisting albuminuria
>2500 mg/24 h) to <600 mg/24 h, sustained for at least 1 year,
was associated with both a reduction in the risk of progressing
to ESKD, and improved survival [15].
The reduction in albuminuria burden aligns with some other
results involving DPP-4i in T2D without NRP [31], but none has
previously examined individuals with severe albuminuria.
Mechanistically, it has been suggested that these effects are not
related to changes in glycaemic control [28], but rather alternate
mechanism, e.g. via attenuation of podocyte injury or inhibition
of myofibroblast transformation [32], or inhibition of
endothelial-to-mesenchymal transition and restoration of
microRNA-29s [33]. The observations of neutral effects on CV
outcomes and kidney composite outcomes, despite a significant
reduction in albuminuria burden, probably suggests that
changes in albuminuria are not strong effect-modifier for CV
disease [34] and that the magnitude of effect is too modest to
modulate risk for kidney outcome [35, 36]. Alternatively, it could
be argued that a median duration of 2.2 years is too short a time
period to be able to modulate the risk for kidney events. The po-
tential heterogeneity of effect for the key kidney outcome we
consider is a play of chance, as this was not observed for harder
kidney outcomes excluding the eGFR component, or when using
other creatinine-based measures in the same composite out-
come (like doubling of creatinine or other eGFR cut-offs).
The observation of a modest subacute effect on eGFR in
those without NRP, i.e. in participants with a better preserved
Linagliptin (N=3494) Placebo (N=3485)
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FIGURE 2: CV, hospitalization and kidney outcomes for LINA versus PBO, overall and by NRP at BL. Renal death, sustained ESKD or sustained decrease of 40% in eGFR
from BL were predefined analysis, whereas the others were post hoc defined analysis. Point estimates on the left side of the curve indicate a positive effect for LINA.
Events and HR (95% CI). Key secondary kidney endpoints: renal death, sustained ESKD or sustained decrease of 40% in eGFR from BL. PY, patient-year. ‡Accompanied
by eGFR (MDRD) <60 mL/min/1.73 m2.
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p=0.25
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p=0.002
Δ 0.60 ± 0.56
p=0.28
Δ 0.04 ± 0.17
p=0.81
BL to week 12
Change per 4 weeks
Week 12 to LVOT
Change per year
FIGURE 3: (A) eGFR slopes (MDRD) from BL to LVOT by NRP at BL. D, between-group difference 6 standard error in slope. (B) eGFR slopes (MDRD) from BL to Week 12,
and from Week 12 to LVOT by NRP at BL. D, between-group difference 6 standard error in slope.
Non-bold p-values are for interaction
Favors linagliptin Favors placebo
Linagliptin Placebo
n (%) Rate/100 PY n (%) Rate/100 PY HR (95% CI) HR (95% CI) p-value
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FIGURE 4: Effects on regression of albuminuria overall and by NRP at BL. HR based on Cox regression analyses in patients treated with one or more dose of study medi-
cation. Sustained regression to normoalbuminuria and sustained regression to normoalbuminuria or microalbuminuria were predefined analysis, whereas the others
were post hoc defined analysis. Point estimates on the right side of the curve indicate a positive effect for LINA. Events and HR (95% CI). PY, patient-year.
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renal function, is consistent with previous reports of DPP-4i [28,
37, 38]. This effect might be related to remission of hyperfiltra-
tion, due to an early natriuretic effect mediated by stromal cell-
derived factor-1a [39] or indirectly via the 2- to 3-fold increase in
GLP-1 levels. The increase in GLP-1 levels induces natriuresis by
reducing the Na/H exchange transporter isoform three-
dependent sodium reabsorption in the proximal tubule and/or
via modulation of more than one of the >40 other substrates
metabolized by DPP-4, including high-mobility group protein
box 1 [40]. In toto, this did not translate into a long-term kidney
benefit, but could potentially explain in part the heterogeneity
of effects when evaluating composite kidney outcomes that in-
clude renal haemodynamic components.
These results from CARMELINA are important, as people
with NRP have limited glucose-lowering therapy options, given
a number of agents are contraindicated or require dose reduc-
tion [11, 41, 42]. This is particularly true for those with
eGFR<45 mL/min/1.73 m2. Furthermore, people with T2D and
NRP could have non-diabetic renal disease, e.g. membranous
nephropathy or immunoglobulin A nephropathy [6, 43], which
we were not able to further characterize in this analysis, as well
as being at particularly increased risk of drug-related adverse
effects [38]. It is therefore particularly important to obtain spe-
cific safety data in this population [5, 10]. Most glucose-lowering
trials of DPP-4i [37, 44–46] have included modest numbers of
participants with CKD, with very few subjects with NRP [13, 29].
In this context, the results presented here not only demonstrate
CV and kidney safety for LINA in NRP and T2D, but also demon-
strate that LINA modestly reduces progression of albuminuria
and increases regression to normoalbuminuria. We also did not
observe an increase in risk for HF in those with NRP and T2D,
which differs from a previous trial with another DPP-4i that in-
dicated an increased risk of hospitalization for HF [47]. In this
particularly frail population, LINA was well tolerated and its
safety profile was comparable to that of PBO.
SGLT-2 inhibitors are now recommended for use relatively
early in T2D, since they have been shown to prevent or slow the
progression of CV and HF events, as well as CKD [2–4, 48]. They
may also have an important role in those with NRP as indicated
in the first dedicated study in a larger proteinuric population
[24] in which 503 of 4401 participants with T2D and CKD had
UACR>3000 mg/g, and in whom the CV and kidney benefits
were consistent with the overall study population. However,
they are still mostly licensed for use in moderate-to-good renal
function, and their glucose-lowering efficacy typically dimin-
ishes with reduced eGFR. Other commonly used medications
for those with NRP and T2D, such as sulphonylureas, which are
associated with hypoglycaemia and are contraindicated in
severe renal function disorders, also require particular monitor-
ing. In this context, LINA may have an important role as
it improves glycaemic control without increasing the risk of
hypoglycaemia [2–4, 45] even in the presence of reduced GFR
and NRP. Thus, an agent such as LINA, which also might
delay insulin initiation [28], might be used to meet the KDIGO
recommendation of an individualized HbA1c target, ranging
from <6.5% to <8.0% in those with T2D and non-dialysis-
dependent CKD [16, 49].
The strengths of this analysis include the large number of
participants with NRP and a pre-specified analysis by NRP at BL.
The trial itself also prospectively captured and centrally adjudi-
cated kidney outcomes. The trial also had some limitations. The
median follow-up was only 2.2 years, many of the other analy-
ses were defined post hoc, and the trial excluded people with BL
eGFR<15 mL/min/1.73 m2 and those receiving dialysis. In addi-
tion, due to the relatively low number of women with events, in
particular in the NRP group, we were unable to perform a reli-
able outcome analysis by sex.
Table 2. AEs occurring until 7 days after treatment discontinuation in CARMELINA by NRP at BL and overall by treatment groups
NRP No NRP Overall
n (%) 646 (100) 6330 (100) 6979 (100)
LINA (317) PBO (329) LINA (3175) PBO (3155) LINA (3494) PBO (3485)
One or more AE 266 (83.9) 287 (87.2) 2429 (76.5) 2435 (77.2) 2695 (77.6) 2722 (78.1)
One or more serious AEs 174 (54.9) 180 (54.7) 1119 (35.2) 1162 (36.8) 1293 (37.2) 1342 (38.5)
AE leading to discontinuation 69 (21.8) 62 (18.8) 289 (9.1) 339 (10.7) 358 (10.3) 401 (11.5)
Aggregated SOC or single preferred terms within category ‘any adverse events’
Infections and infestationsa 99 (31.2) 119 (36.2) 894 (28.2) 988 (31.1) 993 (28.6) 1107 (31.8)
Injury, poisoning and procedural complicationa:
includes fractures
31 (9.8) 29 (8.8) 315 (9.9) 302 (9.6) 346 (10.0) 331 (9.5)
Hypotension 2 (0.6) 0 (0) 44 (1.4) 35 (1.1) 46 (1.3) 35 (1.0)
Peripheral oedema 23 (7.3) 28 (8.5) 107 (3.4) 144 (4.6) 130 (3.7) 172 (4.9)
Hyperkalaemia 10 (3.2) 24 (7.3) 75 (2.4) 74 (2.3) 85 (2.4) 98 (2.8)
Acute kidney injury 19 (6.0) 19 (5.8) 77 (2.4) 83 (2.6) 96 (2.8) 102 (2.9)
Renal impairment 18 (5.7) 26 (7.9) 68 (2.1) 67 (2.1) 86 (2.5) 93 (2.7)
ESKD 22 (6.9) 26 (7.9) 16 (0.5) 19 (0.9) 38 (1.1) 45 (1.3)
Hypoglycaemia
Any hypoglycaemia 108 (34.1) 110 (33.4) 926 (29.2) 914 (29.0) 1034 (29.8) 1024 (29.4)
PG<54 mg/dL or severe hypoglycaemiab 60 (18.9) 68 (20.7) 495 (15.6) 504 (16.0) 555 (16.0) 572 (16.4)
Severe hypoglycaemiab 20 (6.3) 10 (3.0) 86 (2.7) 98 (3.1) 106 (3.1) 108 (3.1)
Missing albuminuria data from three participants, therefore overall not always identical to the sum of subgroups (NRP þ no NRP). aBased on the totality of events
within the SOC. bSevere¼ requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative action.
PG, plasma glucose; SOC, system organ class.
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In conclusion, results from CARMELINA support the view
that LINA has a role in treating patients with T2D and CKD,
including in those complicated by the presence of NRP, by im-
proving glucose control and modestly reducing albuminuria
burden, without increasing CV, kidney risk or AEs, including
hypoglycaemia.
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ployee of Nestlé Health Science. R.T. is a consultant to
Amgen, Boehringer Ingelheim, ZS Pharma, Relypsa, Novo
Nordisk, Reata, AstraZeneca, Bayer and receives grant sup-
port from the NIH. J.R. has served on scientific advisory
boards and received honoraria or consulting fees from Eli
Lilly, Sanofi, Novo Nordisk, Janssen, Oramed, Boehringer
Ingelheim and Intarcia; he has also received grants/research
support from Merck, Pfizer, Sanofi, Novo Nordisk, Eli Lilly,
GlaxoSmithKline, Genentech, Janssen, Lexicon, Boehringer
Ingelheim, Oramed and Intarcia. D.K.M. has received per-
sonal fees from Afimmune, Boehringer-Ingelheim, Janssen
Research and Development LLC, Sanofi-Aventis Group,
Merck Sharp and Dohme, Merck & Co., Lilly USA, Novo
Nordisk, GlaxoSmithKline, AstraZeneca, Lexicon, Eisai Inc.,
Pfizer, Metavant, Applied Therapeutics, Esperion. S.E.K. has
received personal fees from Boehringer Ingelheim, Eli Lilly,
Intarcia, Merck, Novo Nordisk and Pfizer. N.M. has given lec-
tures for Amgen, Boehringer Ingelheim, Sanofi-Aventis,
MSD, BMS, AstraZeneca, Lilly, NovoNordisk; has received
unrestricted research grants from Boehringer Ingelheim;
and has served as an advisor for Amgen, Bayer, Boehringer
Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca and
NovoNordisk. In addition, he has served in trial leadership
for Boehringer Ingelheim and Novo Nordisk. All personal com-
pensation from pharma or device companies are declined.
J.H.A. has received personal fees from Abbvie, Bayer, Bristol-
Myers Squibb, CryoLife, CSL Behring, Novo Nordisk, Pfizer,
Portola, Quantum Genomics, XaTek and Zafgen, and institu-
tional research support from Bayer, Boehringer Ingelheim,
Bristol-Myers Squibb, Cryolife, CSL Behring, Ferring,
Glaxosmithkline and XaTek. B.Z. has received consulting fees
from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen,
Merck, Novo Nordisk and Sanofi Aventis. E.P., S.S., J.T.G. and
N.D.G. are employed by Boehringer Ingelheim. M.v.E. was
employed by Boehringer Ingelheim at the time of conduct of
the study, but is now an employee of Nestlé Health Science.
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